Address
Grafenauweg 8
Leiden, ZH 6300
Netherlands (Kingdom of the)
Phone
31 71 203 6410
Website
Sector
Healthcare
Industry
Biotechnology
Employees
129
First IPO Date
February 04, 2021
| Name | Title | Pay | Year Born |
| Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director | 1.57M | 1959 |
| Maryann Cimino | Director of Corporate Relations | 0 | N/A |
| Wim Souverijns | Chief Commercial Officer | 0 | 1971 |
| Anne Lesage | Chief Early Development Officer | 0 | 1961 |
| Peng Lu | President | 0 | 1978 |
| Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | 0 | 1981 |
| Annick Deschoolmeester | Chief Human Resources Officer | 0 | 1973 |
| David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 0 | 1954 |
| Stefan Abele | Chief Technology Operations Officer | 0 | 1970 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.